3 results
Primary objective:Determine the short- and long-term safety and tolerability of single and multiple doses of NI006 in subjects with ATTR-CM by evaluating adverse events (AE) and serious adverse events (SAE) and changes in laboratory parameters (…
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…
Main objective- To characterize the effect of GLPG2737 on growth in total kidneyvolume (TKV) compared to placebo.- To evaluate the safety and tolerability of oral doses of GLPG2737compared to placebo.Secondary objectives: - To characterize the…